Growth Capital for Lophius Biosciences

Lophius Biosciences GmbH founded in 2002 from the University of Regensburg has been developing and marketing innovative T cell-based diagnostic tests, research tools and diagnostic solutions in the field of infectious diseases and autoimmune diseases since 2008. For the continuation and expansion of the successful company with currently 30 employees, a further round of financing for over 4.25 million € was concluded with the investor VRD GmbH and through the support of the Bavarian Growth Fund with Bayern Kapital, as well as two private investors Wolf Biotech GmbH and WIC GmbH. This fresh capital should be used in particular for the potential of T cell-based expertise in the development of a novel in-vitro diagnostic test to detect active tuberculosis and to place the existing product portfolio further on the market. With 9.5 million cases of  tuberculosis yearly worldwide, and of these 450,000 in Europe alone, this infectious disease is still very much present and early diagnosis is essential for sustainable treatment. The T cell-based test system from Lophius is based on the white blood cells, which serve the immune defence of the body. This test makes fast and direct diagnosis of infectious diseases and autoimmune diseases possible.

 

• Lophius Biosciences GmbH